Table 1. Univariate analyses of progression-free and overall survival in patients with unresectable stage IV gastric cancer treated with S-1/CDDP.
| Characteristics | Number of patients | Median PFS | P-value | Median OS | P-value |
|---|---|---|---|---|---|
|
Age (years, range; 38–78) | |||||
| <60 | 16 (22.9%) | 4.0 | 0.667 | 10.0 | 0.112 |
| ⩾60 |
54 (77.1%) |
5.8 |
|
12.8 |
|
|
Gender | |||||
| Male | 48 (68.6%) | 5.5 | 0.340 | 12.4 | 0.580 |
| Female |
22 (31.4%) |
5.4 |
|
10.3 |
|
|
Performance status | |||||
| 0 | 53 (75.7%) | 5.5 | 0.261 | 14.5 | 0.284 |
| 1–2 |
17 (24.3%) |
5.4 |
|
10.4 |
|
|
Location | |||||
| Fundus | 50 (71.4%) | 4.7 | 0.986 | 10.6 | 0.145 |
| Antrum |
20 (28.6%) |
6.0 |
|
14.6 |
|
|
Macroscopic type | |||||
| Scirrhous | 13 (18.6%) | 3.8 | 0.058 | 10.0 | 0.028 |
| Nonscirrhous |
57 (81.4%) |
5.8 |
|
12.4 |
|
|
Lauren's classification | |||||
| Intestinal | 34 (48.6%) | 5.4 | 0.919 | 13.0 | 0.197 |
| Diffuse |
36 (51.4%) |
5.4 |
|
10.0 |
|
|
Liver metastasis | |||||
| Yes | 31 (44.3%) | 4.8 | 0.136 | 10.2 | 0.176 |
| No |
39 (55.7%) |
6.0 |
|
13.0 |
|
|
Peritoneal dissemination | |||||
| Yes | 31 (44.3%) | 5.4 | 0.956 | 12.4 | 0.427 |
| No |
39 (55.7%) |
5.5 |
|
10.6 |
|
|
Other metastasis | |||||
| Yes | 17 (24.3%) | 4.9 | 0.198 | 10.3 | 0.239 |
| No |
53 (75.7%) |
5.7 |
|
12.4 |
|
|
Number of metastatic organs | |||||
| One | 18 (25.7%) | 6.3 | 0.320 | 12.8 | 0.234 |
| More than two |
52 (74.3%) |
4.8 |
|
11.1 |
|
|
Albumin (mg dl−1, range; 2.2–4.6) | |||||
| <3.5 | 28 (40.0%) | 4.1 | 0.210 | 10.2 | 0.202 |
| ⩾3.5 |
42 (60.0%) |
6.2 |
|
12.4 |
|
|
ALP (IU l−1, range; 96–3696) | |||||
| <339 | 54 (77.2%) | 5.5 | 0.828 | 12.4 | 0.968 |
| ⩾339 |
16 (22.8%) |
6.0 |
|
11.5 |
|
|
CEA (mg dl−1, range; 1–8040) | |||||
| <5.0 | 35 (50.0%) | 5.8 | 0.690 | 13.0 | 0.572 |
| ⩾5.0 |
35 (50.0%) |
4.9 |
|
11.1 |
|
|
CA19-9 (mg dl−1, range; 1–182 500) | |||||
| <37 | 40 (57.4%) | 4.8 | 0.622 | 12.8 | 0.317 |
| ⩾37 | 30 (42.6%) | 5.7 | 10.2 | ||
Abbreviations: ALP=alkaline phosphatase; CA=carbohydrate antigen; CEA=carcinoembryonic antigen; OS=overall survival; PFS=progression-free survival; S-1/CDDP=S-1 and cisplatin.